

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being transmitted via the Office electronic filing system in accordance with § 1.6(a)(4).

Dated: September 19, 2008 Signature: /David A. Gass #38,153/  
(David A. Gass)

Docket No.: 28113/39467A  
(PATENT)

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Patent Application of:  
Kari Alitalo et al.

Application No.: 10/567,630

Confirmation No.: 2853

Filed: May 30, 2006

Art Unit: 1637

For: MATERIALS AND METHODS FOR  
COLORECTAL CANCER SCREENING,  
DIAGNOSIS, AND THERAPY

Examiner: C. B. Wilder

**RESPONSE TO ELECTION OF SPECIES REQUIREMENT**

MS Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

In response to the election of species requirement set forth in the Office Action dated August 19, 2008, Applicants hereby elect species (c) the Beta-catenin/TCF signaling pathway for examination in the above-identified application. The Applicants agree with the U.S. Patent and Trademark Office that claims 34, 36 and 37 are drawn to the elected invention insofar as they specifically refer to a combination therapy that includes an inhibitor of the Beta-catenin/TCF signaling pathway. In addition, claims 17, 21, 22, 25-29, 33, 46, 68 and 70-76 all encompass the elected species insofar as they are generic to the elected combination therapy claims. Even the claims that read on non-elected combinations (31, 33, and 41) do not exclude the elected combination.

The Applicants traverse the election requirement insofar as it is premised on and characterized as a lack of unity requirement. All of the originally elected claims share the *common technical feature recited in claim 17*, for example, relating to the Prox-1 inhibitor. The fact that some of the *dependent* claims specify different *second* agents for

*combination* therapy does not change the fact that all of the originally elected claims have unity.

Applicant believes no fee is due with this response. However, if a fee is due, please charge our Deposit Account No. 13-2855, under Order No. 28113/39467A from which the undersigned is authorized to draw.

Dated: September 19, 2008

Respectfully submitted,

By           /David A. Gass #38,153/            
David A. Gass  
Registration No.: 38,153  
MARSHALL, GERSTEIN & BORUN LLP  
233 S. Wacker Drive, Suite 6300  
Sears Tower  
Chicago, Illinois 60606-6357  
(312) 474-6300  
Attorney for Applicant